Comparison of pituitary adenylate cyclase-activating polypeptide (PACAP, ADCYAP1) gene polymorphisms among patients with methamphetamine addiction, methamphetamine-induced psychosis and healthy controls

Basit Öğe Kaydı
dc.contributor.authorTuran, Cetin
dc.contributor.authorSenormanci, Guliz
dc.contributor.authorSenormanci, Omer
dc.contributor.authorCelik, Sevim Karakas
dc.contributor.authorCakmak, Gunes
dc.contributor.authorDemirci, Onur Okan
dc.date.accessioned2024-03-13T10:30:55Z
dc.date.available2024-03-13T10:30:55Z
dc.date.issued2023
dc.departmentİstanbul Beykent Üniversitesien_US
dc.description.abstractObjective. - Recent studies have shown the role of the PACAPergic system in addiction and psychotic disorders. Studies also show the close association of methamphetamine with psychosis. In our study, we aim to compare the distribution of PACAP rs2856966, rs2231181, and rs1610037 gene polymorphisms, as determined according to literature research, among the patients with methamphetamine addiction (MA), patients with methamphetamine-induced psychosis (MIP), and healthy controls (HC), and to investigate the associations of these polymorphisms with MA and MIP.Methods. - In all, 173 patients diagnosed with MA, 120 patients diagnosed with MIP, and 104 HC without any history of substance abuse were included. Inter-group PACAP rs2856966, rs2231181, and rs1610037 genotypes were examined.Results. - The rs2231181 CC genotype was determined to increase the risk of MA by 2708 times (13 = 2708, P = 0.010) and the risk of MIP by 2786 times (13 = 2786, P = 0.010). The rs1610037 GG genotype was observed to increase the risk of MA by 9322 times (13 = 9322, P < 0.001) and the risk of MIP by 6579 times (13 = 6579, P = 0.004). Conclusion. - Through the PACAPergic system, new treatment interventions specific to MIP and for reducing relapses in MA can be developed. Moreover, treatments to be developed through the PACAPergic system may also be beneficial in preventing the neurotoxicity caused by methamphetamine, by the effect of PACAP on neural development.(c) 2023 Elsevier Masson SAS. All rights reserved.en_US
dc.identifier.doi10.1016/j.amp.2023.02.009
dc.identifier.endpage712en_US
dc.identifier.issn0003-4487
dc.identifier.issn1769-6631
dc.identifier.issue8en_US
dc.identifier.scopus2-s2.0-85149773539en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage707en_US
dc.identifier.urihttps://doi.org/10.1016/j.amp.2023.02.009
dc.identifier.urihttps://hdl.handle.net/20.500.12662/3606
dc.identifier.volume181en_US
dc.identifier.wosWOS:001082539200001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherMasson Editeuren_US
dc.relation.ispartofAnnales Medico-Psychologiquesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectADCYAP1en_US
dc.subjectMethamphetamine addictionen_US
dc.subjectMethamphetamine-induced psychosisen_US
dc.subjectPACAPen_US
dc.titleComparison of pituitary adenylate cyclase-activating polypeptide (PACAP, ADCYAP1) gene polymorphisms among patients with methamphetamine addiction, methamphetamine-induced psychosis and healthy controlsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu